Merck (MRK) Receives Positive EMA CHMP Opinion on KEYTRUDA as Advanced Melanoma Treatment
Tweet Send to a Friend
Merck (NYSE: MRK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE